Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma

Cancer Letters

Volumn 293, Issue 2, 2010, Pages 220-229

  Duan, Zhenfeng ^a   Ji, Diana ^b   Weinstein, Edward J ^b   Liu, Xianzhe ^a   Susa, Michiro ^a   Choy, Edwin ^a   Yang, Cao ^a   Mankin, Henry ^a   Hornicek, Francis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Sigma Aldrich Co   (United States)

Author keywords

Osteosarcoma; PLK1; ShRNA

Indexed keywords

COMPLEMENTARY DNA; LENTIVIRUS VECTOR; POLO LIKE KINASE 1; PROTEIN KINASE INHIBITOR; SCYTONEMIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; INDOLE DERIVATIVE; ONCOPROTEIN; PHENOL DERIVATIVE; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR LIBRARY; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; LENTIVIRINAE; OSTEOSARCOMA; PATHOLOGY; SARCOMA; TUMOR CELL LINE; UPREGULATION;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; INDOLES; LENTIVIRUS; OSTEOSARCOMA; PHENOLS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA; SARCOMA; UP-REGULATION;

EID: 77952518695     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.014     Document Type: Article

References (48)

1. Chou A.J., Geller D.S., Gorlick R. Therapy for osteosarcoma: where do we go from here?. Paediatr. Drugs 2008, 10:315-327.
2. Trent J.C. Rapid evolution of the biology and treatment of sarcoma. Curr. Opin. Oncol. 2008, 20:393-394.
3. Siegel H.J., Pressey J.G. Current concepts on the surgical and medical management of osteosarcoma. Expert Rev. Anticancer Ther. 2008, 8:1257-1269.
4. Chou A.J., Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev. Anticancer Ther. 2006, 6:1075-1085.
5. MacKeigan J.P., Murphy L.O., Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 2005, 7:591-600.
6. Sebolt-Leopold J.S., English J.M. Mechanisms of drug inhibition of signalling molecules. Nature 2006, 441:457-462.
7. Du J., Bernasconi P., Clauser K.R., Mani D.R., Finn S.P., Beroukhim R., Burns M., Julian B., Peng X.P., Hieronymus H., Maglathlin R.L., Lewis T.A., Liau L.M., Nghiemphu P., Mellinghoff I.K., Louis D.N., Loda M., Carr S.A., Kung A.L., Golub T.R. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat. Biotechnol. 2008.
8. Scotlandi K., Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr. Opin. Oncol. 2008, 20:419-427.
9. Cao L., Yu Y., Darko I., Currier D., Mayeenuddin L.H., Wan X., Khanna C., Helman L.J. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008, 68:8039-8048.
10. Wan X., Helman L.J. The biology behind mTOR inhibition in sarcoma. Oncologist 2007, 12:1007-1018.
11. Mita M.M., Tolcher A.W. The role of mTOR inhibitors for treatment of sarcomas. Curr. Oncol. Rep. 2007, 9:316-322.
12. Taniguchi E., Nishijo K., McCleish A.T., Michalek J.E., Grayson M.H., Infante A.J., Abboud H.E., Legallo R.D., Qualman S.J., Rubin B.P., Keller C. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008, 27:6550-6560.
13. George J.A., Chen T., Taylor C.C. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel resistant ovarian cancer cells. Cancer Res. 2005, 65:10381-10388.
14. LeRoith D., Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 2004, 5:201-202.
15. Helman L.J., Meltzer P. Mechanisms of sarcoma development. Nat. Rev. Cancer 2003, 3:685-694.
16. Bosher J.M., Labouesse M. RNA interference: genetic wand and genetic watchdog. Nat. Cell Biol. 2000, 2:E31-E36.
17. Duan Z., Brakora K.A., Seiden M.V. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer Ther. 2004, 3:833-838.
18. Cullen B.R. Induction of stable RNA interference in mammalian cells. Gene. Ther. 2006, 13:503-508.
19. Moffat J., Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., Piqani B., Eisenhaure T.M., Luo B., Grenier J.K., Carpenter A.E., Foo S.Y., Stewart S.A., Stockwell B.R., Hacohen N., Hahn W.C., Lander E.S., Sabatini D.M., Root D.E. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124:1283-1298.
20. Dann C.T. New technology for an old favorite: lentiviral transgenesis and RNAi in rats. Transgenic Res. 2007, 16:571-580.
21. Lourda M., Trougakos I.P., Gonos E.S. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein J. Int. J. Cancer 2007, 120:611-622.
22. Stevenson C.S., Capper E.A., Roshak A.K., Marquez B., Eichman C., Jackson J.R., Mattern M., Gerwick W.H., Jacobs R.S., Marshall L.A. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J. Pharmacol. Exp. Ther. 2002, 303:858-866.
23. Duan Z., Weinstein E.J., Ji D., Ames R.Y., Choy E., Mankin H., Hornicek F.J. Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol. Cancer Ther. 2008, 7:2377-2385.
24. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6:321-330.
25. Nappi T.C., Salerno P., Zitzelsberger H., Carlomagno F., Salvatore G., Santoro M. Identification of polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res. 2009, 69:1916-1923.
26. Yang W.S., Stockwell B.R. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol. 2008, 9:R92.
27. Guan R., Tapang P., Leverson J.D., Albert D., Giranda V.L., Luo Y. Small interfering RNA mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res. 2005, 65:2698-2704.
28. Rizki A., Mott J.D., Bissell M.J. Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res. 2007, 67:11106-11110.
29. Spankuch B., Heim S., Kurunci-Csacsko E., Lindenau C., Yuan J., Kaufmann M., Strebhardt K. Down-regulation of polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res. 2006, 66:5836-5846.
30. Smith M.R., Wilson M.L., Hamanaka R., Chase D., Kung H., Longo D.L., Ferris D.K. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem. Biophys. Res. Commun. 1997, 234:397-405.
31. Lane H.A., Nigg E.A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell Biol. 1996, 135:1701-1713.
32. Cogswell J.P., Brown C.E., Bisi J.E., Neill S.D. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ. 2000, 11:615-623.
33. Liu X.Y., Zhou T., Chang K., Wang L., Zheng M.X., Luo Y.W. Study on intermolecular interaction between 4-aminopyridine and methacrylic acid using two dimensional FTIR spectroscopy. Guang Pu Xue Yu Guang Pu Fen Xi 2008, 28:2073-2076.
34. Liu X., Erikson R.L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:5789-5794.
35. Nogawa M., Yuasa T., Kimura S., Tanaka M., Kuroda J., Sato K., Yokota A., Segawa H., Toda Y., Kageyama S., Yoshiki T., Okada Y., Maekawa T. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J. Clin. Invest. 2005, 115:978-985.
36. Liu X., Lei M., Erikson R.L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol. Cell Biol. 2006, 26:2093-2108.
37. Spankuch B., Matthess Y., Knecht R., Zimmer B., Kaufmann M., Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J. Natl. Cancer Inst. 2004, 96:862-872.
38. Holtrich U., Wolf G., Brauninger A., Karn T., Bohme B., Rubsamen-Waigmann H., Strebhardt K. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc. Natl. Acad. Sci. USA 1994, 91:1736-1740.
39. Hamanaka R., Maloid S., Smith M.R., O'Connell C.D., Longo D.L., Ferris D.K. Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ. 1994, 5:249-257.
40. Wolf G., Elez R., Doermer A., Holtrich U., Ackermann H., Stutte H.J., Altmannsberger H.M., Rubsamen-Waigmann H., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997, 14:543-549.
41. Weichert W., Kristiansen G., Winzer K.J., Schmidt M., Gekeler V., Noske A., Muller B.M., Niesporek S., Dietel M., Denkert C. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch. 2005, 446:442-450.
42. Weichert W., Kristiansen G., Schmidt M., Gekeler V., Noske A., Niesporek S., Dietel M., Denkert C. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J. Gastroenterol. 2005, 11:5644-5650.
43. Strebhardt K., Kneisel L., Linhart C., Bernd A., Kaufmann R. Prognostic value of polo-like kinase expression in melanomas. JAMA 2000, 283:479-480.
44. Yamada S., Ohira M., Horie H., Ando K., Takayasu H., Suzuki Y., Sugano S., Hirata T., Goto T., Matsunaga T., Hiyama E., Hayashi Y., Ando H., Suita S., Kaneko M., Sasaki F., Hashizume K., Ohnuma N., Nakagawara A. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004, 23:5901-5911.
45. Kneisel L., Strebhardt K., Bernd A., Wolter M., Binder A., Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J. Cutan. Pathol. 2002, 29:354-358.
46. Ahr A., Karn T., Solbach C., Seiter T., Strebhardt K., Holtrich U., Kaufmann M. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002, 359:131-132.
47. Ito Y., Nakamura Y., Yoshida H., Tomoda C., Uruno T., Takamura Y., Miya A., Kobayashi K., Matsuzuka F., Kuma K., Kakudo K., Miyauchi A. Polo-like kinase 1 expression in medullary carcinoma of the thyroid: its relationship with clinicopathological features. Pathobiology 2005, 72:186-190.
48. Yamaguchi U., Honda K., Satow R., Kobayashi E., Nakayama R., Ichikawa H., Shoji A., Shitashige M., Masuda M., Kawai A., Chuman H., Iwamoto Y., Hirohashi S., Yamada T. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci. 2009.